Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

Cytochromes P450 (CYP) are a major source of variability in drug pharmacokinetics and
response. Of 57 putatively functional human CYPs only about a dozen enzymes, belonging …

Abstract Tacrolimus (or FK506), a calcineurin inhibitor (CNI) introduced in field of
transplantation in the 1990s, is the cornerstone of most immunosuppressive regimens in …

Cytochrome P450 3A4 (CYP3A4) is involved in the metabolism of more drugs in clinical use
than any other foreign compound–metabolizing enzyme in humans. Recently, increasing …

Tacrolimus (FK506) and cyclosporine (cyclosporin A, CsA) are cornerstone
immunosuppressive agents administered to solid organ transplant recipients to prevent and …

Background: Tacrolimus (Tac, or FK506), a calcineurin inhibitor (CNI), is the first-line
immunosuppressant which consists of the footstone as immunosuppressive regimens in …

The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy
after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has …

Interindividual differences in drug disposition are important causes for adverse drug
reactions and lack of drug response. The majority of phase I and phase II drug-metabolizing …

CYP3A4 is the most important drug metabolizing enzyme in adult humans because of its
prominent expression in liver and gut and because of its broad substrate specificity, which …

Many studies have attempted to explain the interindividual variability observed in drug
metabolism by assessing the impact of SNPs in genes implicated in drug absorption …